Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and FollicularThyroidCancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories. For patients with differentiated thyroid cancer (DTC), that is, papillary thyroid cancer (PTC) and follicularthyroidcancer (FTC), the American Thyroid Association and European Thyroid
Long-term oncological outcomes of follicularthyroidcancer in adolescents and young adults: A nationwide population-based study. Follicular thyroid carcinoma (FTC) in adolescents and young adults (AYAs) is rare and data on long-term oncological outcomes are scarce. This study aimed to describe the long-term recurrence and survival rates of AYAs with FTC, and identify risk factors for recurrence
Evaluating the use of a two-step age-based cutoff for the UICC/AJCC TNM staging system in patients with papillary or follicularthyroidcancer. The joint Union International Contre le Cancer and American Joint Committee on Cancer (UICC/AJCC) Tumor, Node, Metastasis (TNM) staging system for differentiated thyroid cancer (DTC) involves a single age cutoff as a prognostic criterion. Because was analyzed for papillary (PTC) and follicularthyroidcancer (FTC) separately, investigating several two-step age-based cutoffs for those with distant metastases; below lower threshold classified as stage I, between lower and upper threshold as stage II, and above upper threshold as stage IV. We included 3074 DTC patients (77% PTC). For PTC, an age cutoff of 45 with 50 years had the best statistical model
Temporal Trends in Papillary and FollicularThyroidCancer Incidence from 1995 to 2019 in Adults in Denmark According to Education and Income. Thyroid cancer incidence has increased over the past decades. Differences in incidence trends have been observed depending on socioeconomic status. Here, we describe trends in the incidence of papillary thyroid cancer (PTC) and follicularthyroidcancer
Treating papillary and follicularthyroidcancer in children and young people: Single UK-center experience between 2003 and 2018. Differentiated thyroid cancer (DTC) in children and adolescents is rare and data about its presentation and management are not well known. The aim of this study was to provide evidence of the current practice in the United Kingdom before the launch of the Rare
Microsatellite Instability Occurs in a Subset of FollicularThyroidCancers. Inactivation of DNA mismatch repair (MMR) and the resulting microsatellite instability (MSI) are frequently observed in endometrial, stomach, and colorectal cancers, as well as more rarely in other solid tumor types. The prevalence of MSI in thyroid cancer has not been explored in depth, although recent studies
Evaluating the 2015 American Thyroid Association Risk Stratification System in High Risk Papillary and FollicularThyroidCancer Patients. The 2015 American Thyroid Association (ATA) Risk Stratification System for differentiated thyroid cancer (DTC) is designed to predict recurring/persisting disease but not survival. Earlier studies evaluating this system evaluated the 2009 edition, comprised a low number of patients with ATA high-risk, had low numbers of patients with follicularthyroidcancer (FTC), or did not distinguish between papillary and FTC. Therefore, we evaluated the prognostic value of the 2015 ATA Risk Stratification System in a large population of high-risk thyroid cancer patients, which included a substantial proportion of FTC patients. We retrospectively studied adult
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicularthyroidcancer. Treatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety and efficacy of pembrolizumab were evaluated in patients with advanced differentiated thyroid cancer expressing programmed death ligand 1 (PD -L1). Patients with advanced thyroid cancer were enrolled in the nonrandomized, phase Ib KEYNOTE-028 trial conducted to evaluate safety and antitumor activity of the anti-programmed death 1 (PD-1) antibody pembrolizumab in advanced solid tumors. Key eligibility criteria were advanced papillary or follicularthyroidcancer, failure of standard therapy, and PD-L1 expression in tumor or stroma cells
Whole-Exome Sequencing Identifies Two Discrete Druggable Signaling Pathways in FollicularThyroidCancer. Thyroid cancer is the most common endocrine malignancy, with continuously increasing incidence. Follicularthyroidcancer (FTC) accounts for approximately 10% to 15% of these cases and is known to be associated with several gene mutations. The purpose of this study was to identify novel
Comparing the Prognostic Value of the Eighth Edition of the AJCC/TNM Staging System between Papillary and FollicularThyroidCancer. Recently, the eighth edition of the American Joint Committee on Cancer (AJCC)/tumor node metastasis (TNM) staging system for differentiated thyroid cancer (DTC) was published. Studies evaluating this new edition have so far only comprised patients with papillary thyroid cancer (PTC) or made no distinction between PTC and follicularthyroidcancer (FTC). Therefore, this study evaluated the prognostic value of the eighth edition of the AJCC/TNM staging system in a European population with DTC, focusing on potential differences between PTC and FTC. Adult patients with DTC who were diagnosed and/or treated at a Dutch university hospital between January 2002
IAPs cause resistance to TRAIL-dependent apoptosis in follicularthyroidcancer. Follicularthyroidcancer's (FTC) excellent long-term prognosis is mainly dependent on postoperative radioactive iodine (RAI) treatment. However, once the tumour becomes refractory, the 10-year disease-specific survival rate drops below 10%. The aim of our study was to evaluate the prognostic and biological role
Follicularthyroidcancer avid on C-11 Methionine PET/CT A case of follicularthyroidcancer with intense focal Methionine uptake on 11C-Methionine PET/CT is reported here. The use of 11C-Methionine PET in differentiated thyroid cancer is currently being investigated as a surrogate tracer compared to the more widely used 18F-FDG PET. This case illustrates the potential incremental value
Follicularthyroidcancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Follicularthyroidcancer is the second most common differentiated thyroid cancer histological type and has been overshadowed by its more common counterpart-papillary thyroid cancer-despite its unique biological behaviour and less favourable outcomes. In this Review, we comprehensively review the literature on follicularthyroidcancer to provide an evidence-based guide to the management of these tumours, to highlight the lack of evidence behind guideline recommendations, and to identify changes and challenges over the past decades in diagnosis, prognosis, and treatment. We highlight that correct identification of cancer in indeterminate cytological samples is challenging
Prognostic markers in well differentiated papillary and follicularthyroidcancer (WDTC). WDTC (papillary and follicularthyroidcancer) make up around 90% of all thyroid tumours. Overall, the prognosis in patients with WDTC is excellent. However, there are small cohorts of patients who experience a more aggressive form of disease which is often associated with certain poor prognostic factors
Changes in the clinicopathological characteristics and genetic alterations of follicularthyroidcancer. Changes in the clinicopathological characteristics and genetic alterations of follicularthyroidcancer (FTC) over time have not been reported. Moreover, the prognostic effects of and promoter mutations in FTC have not been clearly elucidated. We investigated changes
Comparison of prognostic scoring systems in follicularthyroidcancer INTRODUCTION Many studies have addressed the accuracy of prognostic scoring systems in the treatment of differentiated thyroid cancers as a whole but few have addressed this issue in patients with follicularthyroidcancer (FTC) alone. The aim of this study was to establish the accuracy of the various scoring systems
Proteome Analysis of Human FollicularThyroidCancer Cells Exposed to the Random Positioning Machine Several years ago, we detected the formation of multicellular spheroids in experiments with human thyroid cancer cells cultured on the Random Positioning Machine (RPM), a ground-based model to simulate microgravity by continuously changing the orientation of samples. Since then, we have studied
Benefits and harms of lobectomy versus total thyroidectomy for intermediate/high-risk differentiated (papillary and follicular) thyroidcancer: A Systematic review and meta-analysis PROSPEROInternational prospective register of systematic reviews Print | PDFBenefits and harms of lobectomy versus total thyroidectomy for intermediate/high-risk differentiated (papillary and follicular) thyroid , Daniela Cecilia González-Cruz, Mark L. Urken, Juan Pablo Brito, Michael R. Tuttle, Ricardo Ramirez. Benefits and harms of lobectomy versus total thyroidectomy for intermediate/high-risk differentiated (papillary and follicular) thyroidcancer: A Systematic review and meta-analysis. PROSPERO 2024 CRD42024512957 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024512957Review
Combinatorial Antitumor Effect of Rapamycin and β-Elemene in FollicularThyroidCancer Cells Background. mTOR signaling would be a promising target for thyroid cancer therapy. However, in clinical trials, objective response rate with mTOR inhibitor monotherapy in most cancer types was modest. A new focus on development of combinatorial strategies with rapalogs is increasing. Objective . Investigating the combinatorial antitumor effect of rapamycin and β-elemene in follicularthyroidcancer cells. Methods. MTT assay was used to determine the FTC-133 cell proliferation after culturing with rapamycin and/or β-elemene. To analyze their combinatorial effect, immunoblotting was performed to analyze the activation status of AKT. Moreover, β-elemene attenuated rapamycin-induced immunosuppression